ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1351	National Cancer Institute	Html	en	Osteosarcoma and Malignant Fibrous Histiocytoma of Bone Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of osteosarcoma and malignant fibrous histiocytoma of bone.	high-grade osteosarcoma patients 0.629145 co-operative German-Austrian-Swiss osteosarcoma 0.55607 neoadjuvant cooperative osteosarcoma 0.624122 pediatric osteosarcoma 0.57965 locally recurrent osteosarcoma 0.5543 Primary high-grade osteosarcoma 0.612176 parosteal osteosarcoma 0.568181 conventional osteosarcoma 0.56726 High grade osteosarcoma 0.599621 cooperative osteosarcoma study 0.792783 nonmetastatic osteosarcoma 0.60813 german-austrian-swiss osteosarcoma study 0.647756 high-grade osteosarcoma 0.738641 craniofacial osteosarcoma 0.630712 conventional high-grade osteosarcoma 0.570688 patients 0.646684 radiation-associated craniofacial osteosarcoma 0.580431 European Osteosarcoma Intergroup 0.58771 osteosarcoma incidence rate 0.594537 neoadjuvant chemotherapy 0.670909 high-grade extremity osteosarcoma 0.5876 Extraskeletal osteosarcoma 0.568579 Craniofacial osteosarcoma Experience 0.589537 Group Osteosarcoma Study 0.569569 radiation-related osteosarcoma 0.565185	osteosarcoma skip metastases 0.57865 synchronous multifocal osteosarcoma 0.617106 Osteosarcoma Intergroup study 0.567726 et al. 0.76197 PUBMED Abstract 0.575849 unresectable high-grade osteosarcoma 0.562489 primary osteosarcoma 0.586929 periosteal osteosarcoma 0.560798 osteosarcoma study group 0.793978 recurrent osteosarcoma 0.571668 non-metastatic osteosarcoma 0.633808 multi-institutional osteosarcoma study 0.604239 extremity osteosarcoma 0.634474 metastatic osteosarcoma 0.602383 multiinstitutional osteosarcoma study 0.587612 Abstract 0.808529 Clin Oncol 0.842874 operable osteosarcoma 0.589711 cooperative german-austrian-swiss osteosarcoma 0.615008 primary tumor 0.561916 intermediate-grade osteosarcoma 0.59029 Oncology Group 0.566747 cancer 0.596697 osteosarcoma 0.959056	CLICK HERE
1402	National Cancer Institute	Html	en	Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of childhood non-Hodgkin lymphoma.	T-cell lymphoblastic lymphoma 0.616756 mediastinal B-cell lymphoma 0.654258 Pediatric Non-Hodgkin Lymphoma 0.567507 mature B-cell 0.675642 Engl J Med 0.525188 B-cell non-Hodgkin lymphoma 0.746462 children 0.65412 mature B-cell leukemia 0.544897 cell lymphoma outcome 0.543686 lymphoblastic lymphoma stage 0.540387 pediatric-type follicular lymphoma 0.574777 large B-cell lymphomas 0.528398 large cell lymphoma 0.779097 pediatric anaplastic lymphoma 0.540067 adolescents 0.539146 Burkitt lymphoma 0.638477 mediastinal large B-cell 0.573557 childhood B-cell non-Hodgkin 0.52722 diffuse large b-cell 0.665879 anaplastic large-cell lymphoma 0.616485 center-derived B-cell lymphoma 0.609426 Burkitt lymphoma incidence 0.577758 cell lymphoma cases 0.534062 Leuk Lymphoma 0.529329 large B-cell lymphoma 0.815777	cell lymphoma patients 0.528087 mature B-cell lymphoma 0.609056 et al. 0.801373 Br J Haematol 0.629196 Cairo MS 0.571856 primary mediastinal B-cell 0.5557 Pediatr Blood Cancer 0.817055 childhood B-cell 0.532059 diffuse large-B-cell lymphoma 0.523303 Secondary non-Hodgkin lymphoma 0.572995 mature B-cell non-Hodgkin 0.643468 lymphoblastic lymphoma 0.618923 Abstract 0.750082 cancer group 0.553869 lymphoma 0.902345 Clin Oncol 0.644225 childhood non-Hodgkin lymphoma 0.549011 high-stage Burkitt lymphoma 0.543865 B-cell lymphoma subgroups 0.565819 non-hodgkin lymphoma 0.766463 recurrent non-Hodgkin lymphoma 0.543912 anaplastic large cell 0.660109 oncology group 0.53775 Burkitt-like lymphoma 0.528197	CLICK HERE
1420	National Cancer Institute	Html	en	Prostate Cancer Prevention (PDQ®)–Health Professional Version	Expert-reviewed information summary about factors that may influence the risk of developing prostate cancer and about research aimed at the prevention of this disease.	hereditary prostate cancer 0.542395 prostate biopsy 0.533126 dutasteride group vs 0.459041 skin cancer 0.446356 prostate cancer period 0.528407 cancer mortality rates 0.459369 prostate volume subgroups 0.508967 Prostate Cancer Events 0.558338 finasteride group versus 0.448086 rat ventral prostate 0.516053 high-grade tumors 0.479135 high-grade cancer 0.454168 prostate cancer-specific mortality 0.525559 occult prostate cancer 0.561891 high-grade prostate cancer 0.548137 prostate preventive effects 0.507979 relative risk reduction 0.446967 radical prostatectomy 0.460894 prostate cancer mortality 0.534065 prostate cancer chemoprevention 0.531007 dietary fat 0.445789 men 0.4492 Cancer Events trial 0.451937 negative prostate biopsy 0.515564	digital rectal examination 0.454846 dutasteride group 0.460003 fat intake 0.450377 Cancer Prevention Trial 0.500983 prostate digital 0.500034 prostate cancer risk 0.564597 placebo group 0.469544 incident prostate cancer 0.532469 Cancer Events study 0.447937 prostate volume 0.517049 absolute risk reduction 0.495169 low biologic risk 0.447169 finasteride group 0.448145 prostate cancer 0.910772 Gleason 0.458954 clinical prostate cancer 0.556069 pancake-appearing prostate 0.508749 Prostate Cancer Prevention 0.595277 prostate cancer. 0.505972 prostate cancer death. 0.562581 statistically significant difference 0.470146 prostate cancers 0.559985 human prostate cancer 0.538634	CLICK HERE
1618	National Cancer Institute	Html	en	Late Effects of Treatment for Childhood Cancer (PDQ®)–Patient Version	The treatment of cancer may cause health problems (late effects) for childhood cancer survivors months or years after successful treatment has ended. Get information about the long-term physical, psychological and social effects of treatment for childhood cancer in this expert-reviewed summary.	childhood cancers 0.431043 cancer treatment 0.371211 body 0.373967 childhood cancer survivors 0.770496 chemotherapy 0.372336 PDQ cancer information 0.35879 total-body irradiation 0.354372 ovarian late effects 0.364333 bile duct 0.348106 talk 0.386582 chest radiation treatment 0.353115 kidney late effects 0.373747 joint late effects 0.365129 cancer information summary 0.349224 stem cell transplant 0.480939 pancreatic late effects 0.367016 heart 0.364096 symptoms 0.373794 health problems 0.529948 tests 0.430651 primary cancer diagnosis 0.352818 radiation therapy 0.438948 following 0.347799 hormone replacement therapy 0.348511	late effects 0.94258 treatment 0.571093 blood vessel 0.385075 primary cancer 0.359907 signs 0.42599 related health problems 0.511763 procedures 0.374731 National Cancer Institute 0.350345 spinal cord 0.453656 disease 0.351393 breast cancer risk 0.350432 breast cancer 0.372761 brain tumor 0.349819 thyroid late effects 0.395111 brain 0.380353 doctor 0.354325 radiation treatment 0.379126 radiation 0.476283 acute lymphoblastic leukemia 0.349699 health habits 0.363956 neuroendocrine late effects 0.359016 high blood pressure 0.347712 nonmelanoma skin cancer 0.356812 lung late effects 0.390136	CLICK HERE
1649	National Cancer Institute	Html	en	Aromatherapy and Essential Oils (PDQ®)–Patient Version	Expert-reviewed information summary about the use of aromatherapy and essential oils to improve the quality of life of cancer patients.	PDQ Aromatherapy 0.51751 cancer treatment 0.518478 modern aromatherapy 0.502296 certain essential oils 0.545828 aromatherapy training 0.496531 PDQ cancer information 0.582174 Cancer Complementary 0.49782 hormone -like effects 0.496783 clinical trials 0.646919 cancer information summary 0.54045 aromatherapy massage 0.496545 alternative cancer therapies 0.488792 clinical trial 0.515897 CAM cancer research 0.479249 patients 0.520207 cancer patients 0.499565 Aromatherapy products 0.529674 bergamot essential oil 0.494855 literature discuss aromatherapy 0.518185 NCI PDQ cancer 0.50787 cancer information database 0.486869 aromatherapy 0.710126 international aromatherapy programs 0.515466 Therapies Editorial Board 0.490712	essential oils 0.964677 cancer information 0.591001 treatment 0.540034 Complementary Therapies Editorial 0.514222 Drug Administration 0.547203 Cancer Information Specialist 0.481775 Aromatherapy research 0.515581 tree essential oils 0.64448 Cancer Information Service 0.537651 tree essential oil 0.496279 Antibacterial essential oils 0.531896 National Cancer Institute 0.639762 alternative medicine 0.561892 standard aromatherapy certification 0.518782 term aromatherapy 0.502247 orange essential oil 0.494346 aromatherapy courses 0.496618 tea tree 0.549957 cancer clinical trials 0.48888 alternative therapies 0.505894 ginger essential oil 0.493305 cancer information summaries 0.487611 cancer 0.667969 Holistic Aromatherapy 0.506338	CLICK HERE
1661	National Cancer Institute	Html	en	Antineoplastons (PDQ®)–Health Professional Version	Expert-reviewed information summary about antineoplastons as a treatment for people with cancer.	various tumor suppressor 0.673325 high-risk pediatric patients 0.613742 cell lines 0.732784 antineoplaston A10. 0.614589 steady state concentration 0.632482 mean steady state 0.62987 stable disease 0.629423 tumor suppressor genes 0.670419 antineoplaston a10 0.785651 multiple brain metastases 0.666381 clinical trials 0.642258 cancer cell line 0.621623 cancer information summary 0.628466 highest tumor response 0.628298 patients 0.960903 cancer patients 0.782838 average dose 0.662612 human colon cancer 0.66679 tumor progression 0.629611 colon cancer cells 0.664834 antineoplaston treatment 0.679278 complete tumor response 0.726436 metastatic brain tumor 0.711993 study 0.663173 neutrophil apoptosis 0.623745	Human/Clinical Studies section 0.637915 neoplastic cell lines 0.689948 human blood 0.654645 cancer cells 0.75191 animal tumor systems 0.612469 National Cancer Institute 0.656232 tumor growth 0.643714 breast cancer patients 0.772855 partial tumor response 0.663127 AS2-1 0.676129 antineoplaston therapy 0.747438 white blood cell 0.631532 antineoplaston A. 0.675544 abnormal cells 0.630356 human tumor tissue. 0.623365 human urine 0.617971 antineoplastons 0.86378 experimental cancer therapy 0.633011 chronic lymphocytic leukemia 0.610232 tumor response 0.767878 objective tumor response 0.612044 naturally occurring biochemical 0.637098 antineoplastons A10 0.665762 cancer 0.805413	CLICK HERE
1830	National Cancer Institute	Html	es	Tratamiento de la leucemia mielógena crónica (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de la leucemia mielógena crónica.	imatinib treatment 0.309815 associated with 0.307718 Saglio G 0.311488 Imatinib plus 0.308886 mayoría imatinib 0.309903 with chronic myeloid 0.371977 Sin embargo 0.315782 Kantarjian HM 0.372759 standard-dose imatinib therapy 0.309084 myeloid leukemia patients 0.32923 Cortes JE 0.313764 chronic myeloid leukemia 0.996248 or imatinib 0.327327 myelogenous leukemia patients 0.309285 Philadelphia chromosome-positive 0.307544 TCM alogénico 0.343658 chronic myelomonocytic leukemia 0.306491 patients with chronic 0.376511 Rosti G 0.305694 leucemia mielógena 0.3214 stem cell transplantation 0.309631 chronic myelogenous leukemia 0.537094 with imatinib 0.31893 Guilhot F 0.305867 vs imatinib 0.308365	Chronic Leukemia 0.308312 Versus Imatinib Study 0.318542 patients with philadelphia 0.308802 dasatinib or imatinib 0.311418 versus imatinib 0.331295 Jabbour E 0.308732 patients with 0.421072 myeloid leukemia treated 0.313347 Treatment-Naïve Chronic Myeloid 0.309823 marrow transplantation 0.313614 leukemia treated with 0.314928 Dasatinib Versus Imatinib 0.321251 bone marrow transplantation 0.310388 Leukemia Patients Trial 0.308496 newly diagnosed chronic 0.341689 treated with imatinib 0.310526 imatinib depends 0.308315 imatinib versus 0.310194 chronic granulocytic leukemia 0.306345 tirosina cinasa 0.443764 Clin Oncol 0.407181 bone marrow 0.312247 myelogenous leukemia with 0.307043 treated with 0.317153	CLICK HERE
2015	National Cancer Institute	Html	es	Prevención del cáncer de pulmón (PDQ®)–Versión para pacientes	Sumario de información revisada por expertos sobre factores que influirían en el riesgo de presentar cáncer de pulmón y sobre las investigaciones dirigidas a la prevención de esta enfermedad.	cigarrillo encendido 0.533546 voluntarios sanos 0.521783 secciones llamadas lóbulos 0.564444 factor protector 0.54356 rayos x 0.525531 rayos gamma 0.526755 altas cantidades 0.523911 vías respiratorias 0.534485 suplementos vitamina 0.527073 membrana delgada llamada 0.563077 National Cancer Institute 0.526876 Más personas 0.538369 Instituto Nacional 0.548081	antecedentes familiares 0.770813 siguientes factores 0.598507 Physician Data Query 0.601335 gas radón 0.544843 prevención revisa 0.523285 PDQ Prevención 0.542908 siguientes sustancias 0.533013 Menor exposición 0.544963 órganos respiratorios 0.535883 principal causa 0.53309 factores protectores 0.947087 siguientes sumarios 0.567797 suplementos alimenticios 0.525893	CLICK HERE
2037	National Cancer Institute	Html	es	Prevención del cáncer de piel (PDQ®)–Versión para profesionales de salud	Sumario de información revisada por expertos sobre factores que pueden influir en el riesgo de presentar cáncer de piel y sobre las investigaciones dirigidas a prevenir esta enfermedad.	skin cancer 0.991265 cutaneous melanoma 0.469757 Lippincott Williams 0.41932 skin cancer prevention 0.612003 prevent skin 0.440602 protectores solares 0.469609 Williams GM 0.418343 queratosis solares 0.585992 Sin embargo 0.685934 protector solar 0.843096 American Cancer Society 0.553421 Prev Med 0.458565 cancer prevention study 0.448174 case-control study 0.424296 Study Group 0.427125 DeVita VT Jr 0.43478 risk factors 0.435855 with nonmelanoma skin 0.42056 isotretinoin-basal cell carcinomas 0.418488 randomized trial 0.462527 exposición solar 0.710997 Natl Cancer Inst 0.487884 8th ed 0.41947 protección solar 0.624745 melanoma risk factors 0.418328	pruebas insuficientes 0.419855 Nambour Skin Cancer 0.466485 cell carcinomas 0.512878 Halliday GM 0.422507 Arch Dermatol 0.425176 Wilson LD 0.417928 Cancer Facts 0.43005 Aasi SZ 0.421096 nevos melanocíticos benignos 0.418665 protector solar ayuda 0.422241 controlled trial 0.45893 protector solar versus 0.425736 Epidemiol Biomarkers Prev 0.463973 exposición solar aguda 0.467654 Cancer Prevention Trial 0.454925 Thomas VD 0.418204 Reduce Actinic Cancer 0.419285 radiación uv 0.425436 randomized controlled trial 0.440826 radiación solar 0.432514 crema base 0.420169 nonmelanoma skin cancer 0.715174 radiación ultravioleta 0.572893 Cancer Study Group 0.420229	CLICK HERE
16851	National Cancer Institute	Html	es	Sulfato de hidracina (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos sobre el uso del sulfato de hidracina como tratamiento para personas con cáncer. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta.	Centro Nacional 0.533358 determinados efectos 0.530508 New Hampshire Avenue 0.523784 siguientes aspectos 0.523737 Drug Administration 0.514799 patients with weight 0.533925 NCI Best Case 0.549835 diagnosed non-small-cell lung 0.536234 Grosvenor M 0.517103 datos bibliográficos pubmed 0.525622 siguientes preguntas 0.515807 Heber D 0.517667 siguientes riesgos 0.519241 Instituto Nacional 0.7207 Su JQ 0.518581 Salud Complementaria 0.556196 Visuals Online 0.516984 siguientes resultados 0.521312 curso estudios 0.529991 complementarias revisa 0.524603	Clin Oncol 0.521025 Physician Data Query 0.597613 Goldberg RM 0.517983 PDQ Sulfato 0.709455 Estados Unidos 0.833671 Chlebowski RT 0.553534 breakdown measured 0.519564 libre uso 0.517176 compañía farmacéutica 0.520309 página manejo 0.515736 ¿El tratamiento 0.532073 Bulcavage L 0.518136 patients with 0.551924 siguientes datos 0.520348 ¿Los beneficios 0.514828 juntos cam 0.514239 Funcionamiento motor 0.518326 Tayek JA 0.519355 Series Program 0.514501 medicina complementaria 0.982503	CLICK HERE